Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR-/- mice induced by different DNA vaccination regimens

Vaccine

Volumn 28, Issue 17, 2010, Pages 2937-2944

  Lorenzo, Gema ^a   Martín Folgar, Raquel ^a   Hevia, Esther ^a   Boshra, Hani ^a   Brun, Alejandro ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

DNA vaccine; IFNAR mice; RVFV

Indexed keywords

DNA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; LYMPHOBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL PROLIFERATION; HUMANS; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTOR, INTERFERON ALPHA-BETA; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, DNA; VIRAL PROTEINS; VIRAL VACCINES;

EID: 77949659283     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.018     Document Type: Article

References (29)

1. Gerdes G.H. Rift Valley fever. Rev Sci Technol 23 August (2) (2004) 613-623
2. Bird B.H., Ksiazek T.G., Nichol S.T., and Maclachlan N.J. Rift Valley fever virus. J Am Vet Med Assoc 234 April (7) (2009) 883-893
3. Billecocq A., Spiegel M., Vialat P., Kohl A., Weber F., Bouloy M., et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 78 September (18) (2004) 9798-9806
4. Le May N., Dubaele S., Proietti De Santis L., Billecocq A., Bouloy M., and Egly J.M. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116 February (4) (2004) 541-550
5. Ikegami T., Narayanan K., Won S., Kamitani W., Peters C.J., and Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 5 February (2) (2009) e1000287
6. Kark J.D., Aynor Y., and Peters C.J. A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am J Epidemiol 116 November (5) (1982) 808-820
7. Pittman P.R., Liu C.T., Cannon T.L., Makuch R.S., Mangiafico J.A., Gibbs P.H., et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18 August (1-2) (1999) 181-189
8. Smithburn K. Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 30 February (1) (1949) 1-16
9. Randall R., Gibbs Jr. C.J., Aulisio C.G., Binn L.N., and Harrison V.R. The development of a formalin-killed Rift Valley fever virus vaccine for use in man. J Immunol 89 November (1962) 660-671
10. Barnard B.J. Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 50 September (3) (1979) 155-157
11. Harrington D.G., Lupton H.W., Crabbs C.L., Peters C.J., Reynolds J.A., and Slone Jr. T.W. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res 41 October (10) (1980) 1559-1564
12. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 78 June (6) (2006) 787-791
13. Moussa M.I., Abdel-Wahab K.S., and Wood O.L. Experimental infection and protection of lambs with a minute plaque variant of Rift Valley fever virus. Am J Trop Med Hyg 35 May (3) (1986) 660-662
14. Hubbard K.A., Baskerville A., and Stephenson J.R. Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever. Am J Vet Res 52 January (1) (1991) 50-55
15. Bird B.H., Albarino C.G., Hartman A.L., Erickson B.R., Ksiazek T.G., and Nichol S.T. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 82 March (6) (2008) 2681-2691
16. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., and Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24 November (49-50) (2006) 7181-7189
17. Naslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385 March (2) (2009) 409-415
18. Spik K., Shurtleff A., McElroy A.K., Guttieri M.C., Hooper J.W., and Schmaljohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24 (2006) 4657-4666
19. Lagerqvist N., Naslund J., Lundkvist A., Bouloy M., Ahlm C., and Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6 (2009) 6
20. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 75 February (3) (2001) 1371-1377
21. Calvo-Pinilla E., Rodriguez-Calvo T., Anguita J., Sevilla N., and Ortego N. Establishment of a bluetongue virus infection model in mice that are deficient in the Alpha/Beta interferon receptor. PLoS ONE 4 (2009) e5171
22. Caplen H., Peters C.J., and Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 October (Pt 10) (1985) 2271-2277
23. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 June (5167) (1994) 1918-1921
24. Lorenzo G., Martin-Folgar R., Rodriguez F., and Brun A. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 26 (2008) 5255-5262
25. Liu L., Celma C.C., and Roy P. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virol J 5 (2008) 82
26. Kolumam G.A., Thomas S., Thompson L.J., Sprent J., and Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202 September (5) (2005) 637-650
27. Havenar-Daughton C., Kolumam G.A., and Murali-Krishna K. Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176 March (6) (2006) 3315-3319
28. Gerrard S.R., and Nichol S.T. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 357 January (2) (2007) 124-133
29. Savellini G.G., Di Genova G., Terrosi C., Di Bonito P., Giorgi C., Valentini M., Docquier J.D., and Cusi M.G. Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. Virology 375 (2008) 521-528